Wegovy 0.25 mg 1 Prefilled Pen 1.5 ml

Wegovy 0.25 mg 1 Prefilled Pen 1.5 ml :

Wegovy contains semaglutide, a human glucagon-like peptide-1 (GLP-1) receptor agonist produced using recombinant DNA technology.

It acts as an agonist of GLP-1 receptors helping to regulate appetite and calorie intake by acting on brain areas involved in appetite regulation.

Why use it?

Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adults with:

Initial body mass index (BMI) of ≥30 kg/m² (obesity)

Body mass index from ≥27 kg/m² to less than 30 kg/m² (overweight) with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)

How to use:

Wegovy is administered as a subcutaneous injection once weekly in the abdomen, thigh, or upper arm.

The maintenance dose of 2.4 mg is reached over a gradual 16-week dose escalation period to reduce gastrointestinal side effects.

Dose escalation schedule:

Weeks 1 to 4: 0.25 mg once weekly

Weeks 5 to 8: 0.5 mg once weekly

Weeks 9 to 12: 1 mg once weekly

Weeks 13 to 16: 1.7 mg once weekly

Week 17 and beyond: 2.4 mg once weekly (maintenance dose)

Inject at any time of the day, with or without meals.

What should I do if I miss a dose?

If a dose is missed, it should be given as soon as possible within 5 days after the missed dose.

If more than 5 days have passed, skip the missed dose and resume the regular schedule.

The weekly administration day can be changed if necessary, as long as the time between two doses is at least 3 days (> 72 hours).

Important information:

Not recommended for patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) or end-stage renal disease.

Not recommended for patients with severe hepatic impairment; use with caution in patients with moderate to mild hepatic impairment.

May cause gastrointestinal adverse reactions that can lead to dehydration. Patients should take precautions to avoid fluid depletion.

Acute pancreatitis has been observed with GLP-1 receptor agonists. Discontinue if pancreatitis is suspected.

Should not be used as a substitute for insulin in patients with type 2 diabetes.

Cannot be used with other GLP-1 receptor agonist products.

May increase the risk of hypoglycemia when used with insulin or sulfonylureas in patients with type 2 diabetes.

Not recommended during pregnancy or breastfeeding.

Women of childbearing potential should use contraception during treatment.

Should be discontinued at least two months before planned pregnancy.

Not recommended for patients under 18 years of age.

Ingredients:

Active ingredient:

semaglutide (human GLP-1 analogue produced in saccharomyces cerevisiae cells by recombinant DNA technology)

Concentration varies by pen:

0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg of semaglutide per dose

Inactive ingredients:

disodium phosphate dihydrate

Sodium chloride

Hydrochloric acid (for pH adjustment)

Sodium hydroxide (for pH adjustment)

Water for injection

Additional ingredients in Flextouch pens:

Propylene glycol

Phenol

Storage:

Store in the refrigerator (2 degrees Celsius - 8 degrees Celsius). Do not freeze.

Unused single-use pens can be stored for up to 28 days at temperatures not exceeding 30 degrees Celsius.

Flextouch pens after first use: Can be stored for up to 6 weeks below 30 degrees Celsius or in the refrigerator (2 degrees Celsius - 8 degrees Celsius).